US EditionPublished • loading... • Updated
BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit
Investors seek to lead a securities fraud lawsuit after Boston Scientific's stock dropped sharply due to alleged misleading statements about its Electrophysiology segment performance.
- On March 16, 2026, Rosen Law Firm, P.A. and Levi & Korsinsky, LLP notified purchasers who bought BSX between July 23, 2025 and February 3, 2026 that a class action has been filed and reminded them the lead plaintiff filing deadline is May 4, 2026.
- Plaintiffs allege management knowingly overstated EP growth and sustainability, claiming Boston Scientific projected 15% long-range EP growth despite decelerating U.S. procedure volumes and touted FARAPULSE as "uniquely positioned to lead."
- Shares plunged after the February 4, 2026 disclosure as Boston Scientific elevated full-year 2025 guidance from 18%-19% to approximately 20%, despite alleged unreliable EP growth assumptions.
- Rosen Law Firm, P.A. and Levi & Korsinsky, LLP invited eligible purchasers to join via online claims portal or contact, offering contingency-fee compensation.
- Levi & Korsinsky, LLP's ISS Top 50 ranking and extensive experience in securities litigation underscore its litigation expertise and resources.
Insights by Ground AI
13 Articles
13 Articles
Coverage Details
Total News Sources13
Leaning Left2Leaning Right1Center6Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 22%
C 67%
11%
Factuality
To view factuality data please Upgrade to Premium
